Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
Publication
, Journal Article
Boffito, M; Waters, L; Cahn, P; Paredes, R; Koteff, J; Van Wyk, J; Vincent, T; Demarest, J; Adkison, K; Quercia, R
Published in: AIDS Research and Human Retroviruses
January 1, 2020
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
AIDS Research and Human Retroviruses
DOI
EISSN
1931-8405
ISSN
0889-2229
Publication Date
January 1, 2020
Volume
36
Issue
1
Start / End Page
13 / 18
Publisher
Mary Ann Liebert Inc
Related Subject Headings
- Virology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Boffito, M., Waters, L., Cahn, P., Paredes, R., Koteff, J., Van Wyk, J., … Quercia, R. (2020). Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection. AIDS Research and Human Retroviruses, 36(1), 13–18. https://doi.org/10.1089/aid.2019.0171
Boffito, Marta, Laura Waters, Pedro Cahn, Roger Paredes, Justin Koteff, Jean Van Wyk, Tia Vincent, James Demarest, Kimberly Adkison, and Romina Quercia. “Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.” AIDS Research and Human Retroviruses 36, no. 1 (January 1, 2020): 13–18. https://doi.org/10.1089/aid.2019.0171.
Boffito M, Waters L, Cahn P, Paredes R, Koteff J, Van Wyk J, et al. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection. AIDS Research and Human Retroviruses. 2020 Jan 1;36(1):13–8.
Boffito, Marta, et al. “Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.” AIDS Research and Human Retroviruses, vol. 36, no. 1, Mary Ann Liebert Inc, Jan. 2020, pp. 13–18. Crossref, doi:10.1089/aid.2019.0171.
Boffito M, Waters L, Cahn P, Paredes R, Koteff J, Van Wyk J, Vincent T, Demarest J, Adkison K, Quercia R. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection. AIDS Research and Human Retroviruses. Mary Ann Liebert Inc; 2020 Jan 1;36(1):13–18.
Published In
AIDS Research and Human Retroviruses
DOI
EISSN
1931-8405
ISSN
0889-2229
Publication Date
January 1, 2020
Volume
36
Issue
1
Start / End Page
13 / 18
Publisher
Mary Ann Liebert Inc
Related Subject Headings
- Virology
- 1103 Clinical Sciences